Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Virobay, Inc.
Bind couples with Merck; Idera connects with DMD patients; Mast, CTI BioPharma price offerings; and three companies prices IPOs, including INC Research, a CRO.
Biotechnology companies launched half of the initial public offerings completed by venture capital-backed companies in 2014, but the momentum behind the IPO boom is slowing.
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced August-September 2014.
The market for initial public offerings has been especially frothy for biotechnology companies during the past two years and the week of 15 to 19 September may illustrate perfectly the strange dichotomy at work in the IPO space.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.